Improving Disease Management through Innovative Microbiology Solutions

DeepChek®
Genotyping through NGS & Sanger Sequencing
  • HIV
  • SARS CoV-2
  • HCV
  • TB
  • 16S RNA
More information

Atout Capital a conseillé ABL Diagnostics pour la fusion-absorption de l’activité diagnostic médical d’ABL France à hauteur de 28 m€

Atout Capital a conseillé ABL Diagnostics pour la fusion-absorption de l’activité diagnostic médical d’ABL France à hauteur de 28 m€ ABL DIAGNOSTICS développe, fabrique et commercialise des kits de tests de diagnostic par détection moléculaire et de tests de génotypage par séquençage d’ADN, ciblant des maladies infectieuses chroniques. ABL DIAGNOSTICS a ainsi développé des produits

Read More »

ABL Diagnostics at the Federation of Infection Societies congress

ABL Diagnostics at the Federation of Infection Societies congress Discover the scientific publications from our Innovation team and get more information about new products & services including:  Publication #1 (Poster n°98) Whole Genome Sequencing of Human BK Polyomavirus Using Next-Generation Sequencing View Descamps Veronique1,  Morel Virginie1,  Olivia Ardizzoni,   Amira Doudou,  Chalom Sayada,  Sofiane Mohamed, and Brochot

Read More »

Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) is now ABL Diagnostics SA

Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) is now ABL Diagnostics SA On September 1st 2022, Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) merged into ABL Diagnostics SA (ABLD), a worldwide leading international company, listed on Euronext Paris compartment C (ISIN FR001400AHX6), offering innovative and proprietary molecular biology assays and end-to-end

Read More »

Subscribe to our newsletter

Scroll to Top